Determinants and Prognostic Impact of In-Hospital Sodium-Glucose Cotransporter-2 Inhibitor Initiation in Patients with Heart Failure.

Overall, the proportion of patients prescribed SGLT2i was higher in 2023–2024 than in 2021–2022; however, the difference did not reach statistical significance (LVEF < 40%: 41.3% [31/75 patients] vs 51.3% [41/80]; 40% ≤ LVEF < 50%: 26.7% [8/30] vs 34.9% [15/43]; LVEF ≥ 50%: 21.4% [22/103] vs 30.9% [42/136]).

also in 111,027 other papers

The initiation rate by LVEF was 50% of patients with an LVEF < 40%, 36% of those with 40% ≤ LVEF < 50%, and 29% in those with an LVEF ≥ 50%, showing a decreasing trend with a higher LVEF (Fig. 2 A).

also in 47,180 other papers